Hospitalization risk following initiation of highly active antiretroviral therapy

HIV Medicine

Volumn 11, Issue 5, 2010, Pages 289-298

  Berry, S A ^a   Manabe, Y C ^a   Moore, R D ^a   Gebo, K A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS defining illness; Antiretroviral therapy; Healthcare utilization; Hospitalization; Immune reconstitution

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL PNEUMONIA; CELLULITIS; COMORBIDITY; CONTROLLED STUDY; CRYPTOCOCCOSIS; ESOPHAGUS CANDIDIASIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OPPORTUNISTIC INFECTION; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT RESPONSE; URBAN POPULATION; ADOLESCENT; BLOOD; CD4 LYMPHOCYTE COUNT; HEALTH SERVICE; HIV INFECTIONS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; STATISTICS AND NUMERICAL DATA; TIME; UTILIZATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); RNA, VIRAL; TIME FACTORS; URBAN HEALTH SERVICES; YOUNG ADULT;

EID: 77953152370     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00776.x     Document Type: Article

References (40)

1. Buchacz K, Baker RK, Moorman AC. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS 2008, 22:1345-1354.
2. Palella FJ, Baker RK, Moorman AC. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006, 43:27-34.
3. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003, 362:1267-1274.
4. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr 2005, 40:609-616.
5. Gebo KA, Diener-West M, Moore RD. Hospitalization rates differ by hepatitis C status in an urban HIV cohort. J Acquir Immune Defic Syndr 2003, 34:165-173.
6. Floris-Moore M, Lo Y, Klein RS. Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003, 34:331-337.
7. Mocroft A, Monforte A, Kirk O. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Med 2004, 5:437-447.
8. Betz ME, Gebo KA, Barber E. Patterns of diagnoses in hospital admissions in a multistate cohort of HIV-positive adults in 2001. Med Care 2005, 43:III3-III14.
9. Pulvirenti JJ, Glowacki R, Muppiddi U. Hospitalized HIV-infected patients in the HAART era: a view from the inner city. AIDS Patient Care STDS 2003, 17:565-573.
10. Paul S, Gilbert HM, Lande L. Impact of antiretroviral therapy on decreasing hospitalization rates of HIV-infected patients in 2001. AIDS Res Hum Retroviruses 2002, 18:501-506.
11. Fielden SJ, Rusch ML, Levy AR. Predicting hospitalization among HIV-infected antiretroviral naive patients starting HAART: determining clinical markers and exploring social pathways. AIDS Care 2008, 20:297-303.
12. Paul S, Gilbert HM, Ziecheck W, Jacobs J, Sepkowitz KA. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999, 13:415-418.
13. Casalino E, Wolff M, Ravaud P, Choquet C, Bruneel F, Regnier B. Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS 2004, 18:1429-1433.
14. Nuesch R, Geigy N, Schaedler E, Battegay M. Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV-infected patients. Eur J Clin Microbiol Infect Dis 2002, 21:684-687.
15. Gebo KA, Diener-West M, Moore RD. Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 27:143-152.
16. Mocroft A, Barry S, Sabin CA. The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. AIDS 1999, 13:1255-1261.
17. Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med 2000, 162:64-67.
18. Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis 2007, 45:1369-1374.
19. Elixhauser A, Steiner C, Palmer L. Clinical Classifications Software (CCS), 2008 Rockville, MD, U.S. Agency for Healthcare Research and Quality
20. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993, 269:729-730. The Centers for Disease Control and Prevention.
21. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004, 18:1615-1627.
22. Meintjes G, Lawn SD, Scano F. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8:516-523.
23. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986, 42:121-130.
24. Stata Statistical Software: Release 10 2007, StataCorp., College Station, TX, StataCorp LP
25. Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007, 46:456-462.
26. Fleishman JA, Gebo KA, Reilly ED. Hospital and outpatient health services utilization among HIVinfected adults in care 2000-2002. Med Care 2005, 43:III40-III52.
27. Fielden SJ, Rusch ML, Yip B. Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naive patients started on HAART. J Int Assoc Phys AIDS Care (Chicago, IL) 2008, 7:238-244.
28. Bosch RJ, Wang R, Vaida F, Lederman MM, Albrecht MA. Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment. J Acquir Immune Defic Syndr 2006, 43:433-435.
29. Bucy RP, Hockett RD, Derdeyn CA. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999, 103:1391-1398.
30. Lederman MM, Connick E, Landay A. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS clinical trials group protocol 315. J Infect Dis 1998, 178:70-79.
31. Obel N, Thomsen HF, Kronborg G. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007, 44:1625-1631.
32. Friis-Moller N, Reiss P, Sabin CA. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735.
33. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006, 42:418-427.
34. French MA, Lenzo N, John M. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000, 1:107-115.
35. Jean-Jacques M, Walensky RP, Aaronson WH, Chang Y, Freedberg KA. Late diagnosis of HIV infection at two academic medical centers: 1994-2004. AIDS Care 2008, 20:977-983.
36. Chen RY, Accortt NA, Westfall AO. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006, 42:1003-1010.
37. Schackman BR, Gebo KA, Walensky RP. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006, 44:990-997.
38. Wilson IB, Landon BE, Marsden PV. Correlations among measures of quality in HIV care in the United States: cross sectional study. BMJ 2007, 335:1085-1088.
39. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000, 342:1416-1429.
40. Guidance for Industry: Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval 2002, Rockville, MD, Center for Drug Evaluation and Research, Food and Drug Administration